Optiray
Molecular iodine
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 807.
Registration
- Applicants
- 1
- Registrations
- 3
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Optiray 300 - 500 ML EACH 1,0 ml SOLUTION CONTAINS IOVERSOL EQUIVALENT TO IODINE 300,0 mg | 500 ml 300 - | 34009934/28/0099 | Registered | Not determined | PIPIL |
| Optiray 320 - 500 ML EACH 1,0 ml SOLUTION CONTAINS IOVERSOL EQUIVALENT TO IODINE 320,0 mg | 500 ml 320 - | 34010034/28/0100 | Registered | Not determined | PIPIL |
| Optiray 300 - 75 ML EACH 1,0 ml SOLUTION CONTAINS IOVERSOL EQUIVALENT TO IODINE 300,0 mg | 75 ml 300 - | A390614A39/28/0614 | Cancelled | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Iomeprol
Consolidated Schedules 06 July 2026, line 6786
S1: Iodine
- in oral preparations or mixtures containing more than 150 µg of Iodine per recommended daily dose alone or in combination with other active pharmaceutical ingredients. (S0)
Consolidated Schedules 06 July 2026, lines 566 to 569
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.